Across TCGA pan-cancer cohorts, IGLV3-12 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated IGLV3-12 data layer compared with 20 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in kidney chromophobe (KICH), where higher IGLV3-12 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated IGLV3-12 expression acts as an unfavorable survival marker.
KICH and LGG are the cancer types where IGLV3-12 Mutation most reproducibly stratifies survival.